Skip to content

Saturday, October 24, 2026

Author

Dr. Nathan Pryce

Covers the biotech industry: pipelines, financing and FDA decisions.

Articles by Dr. Nathan Pryce

Two analysts comparing printed abstract pages against a journal proof under the cold white light of a glass-walled meeting room.

Why a Conference Abstract Is Not a Publication: Reading Meeting Data With Caution

Dr. Nathan Pryce

A gloved scientist loading assay plates under cool laboratory lighting, glass and steel surfaces reflecting teal.

How Biomarkers and Companion Diagnostics Decide Who Gets Which Therapy

Dr. Nathan Pryce

A researcher reviewing printouts of quarterly figures beside a laptop at a glass-walled laboratory office, cool daylight on brushed steel.

How Biotech Earnings Season Actually Works for Industry Readers

Dr. Nathan Pryce

A scientist in a white coat examining labeled bioreactor sample vials in a cold, glass-lined biologics quality-control lab.

Celltrion and Teva's Truxima Becomes First Interchangeable Rituximab Biosimilar in the US

Dr. Nathan Pryce

A technician in full cleanroom gowning inspects a stainless-steel bioreactor vessel through glass, cool white and teal light, no logos.

Biologics Manufacturing Explained: From Cell Bank to Vial

Dr. Nathan Pryce

A scientist in safety glasses pipettes samples at a glass-and-steel bench, cool teal light and shallow depth of field.

Anatomy of a Biotech Licensing Deal: Upfronts, Milestones and Tiered Royalties

Dr. Nathan Pryce